ImmunityBio

Inducing Immunogenic Cell Death By Orchestrating the Innate (NK) and Adaptive (T Cell) Immune System

Careers

Join our fast-growing immunotherapy company. We offer you the chance to work with a team that is focused on building something impactful.

About Us

ImmunityBio, Inc. is a privately held immunotherapy company with one of the broadest portfolios of biological molecules spanning albumin-linked chemotherapeutic, peptides, fusion proteins, cytokine, monoclonal antibodies, adenovirus and yeast vaccine therapies.

Recent News

Oct 21, 2020
ImmunityBio, NantKwest Announce First Patient Dosed in Phase 1 Clinical Trial of Novel COVID-19 Vaccine Candidate hAd5

Learn more about the science behind COVID-19

Recent News

Oct 21, 2020
ImmunityBio, NantKwest Announce First Patient Dosed in Phase 1 Clinical Trial of Novel COVID-19 Vaccine Candidate hAd5

About Us

ImmunityBio, Inc. is a privately held immunotherapy company with one of the broadest portfolios of biological molecules spanning albumin-linked chemotherapeutic, peptides, fusion proteins, cytokine, monoclonal antibodies, adenovirus and yeast vaccine therapies.

Careers

Join our fast-growing immunotherapy company. We offer you the chance to work with a team that is focused on building something impactful.

Learn more about the science behind COVID-19

Contact Us

ImmunityBio, Inc.

© 2020 ImmunityBio, Inc. All rights reserved.

Privacy | Terms of Use.

© 2020 ImmunityBio, Inc. All rights reserved.

Privacy | Terms of Use.